Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 7/20 | 0.48 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.48 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.48 |
| ▸ | CLK1 | P49759 | 2/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.48 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.48 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.48 |
| ▸ | PIM1 | P11309 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6186723 | 1.00 | PIK3CG (0.48) | PIK3CGHSPD1HSPE1DYRK1ACSNK2A2 | |
| SCHEMBL6177603 | 0.95 | PIK3CG (0.47) | PIK3CGHSPD1HSPE1DYRK1ACSNK2A2 | |
| SCHEMBL6177606 | 0.95 | PIK3CG (0.47) | PIK3CGHSPD1HSPE1DYRK1ACSNK2A2 | |
| SCHEMBL6185488 | 0.90 | PIK3CG (0.54) | PIK3CGDYRK1ACSNK2A2CLK1CSNK2B | |
| SCHEMBL6185491 | 0.90 | PIK3CG (0.54) | PIK3CGDYRK1ACSNK2A2CLK1CSNK2B | |
| SCHEMBL6185176 | 0.88 | PIK3CG (0.53) | PIK3CGDYRK1ACSNK2A2CLK1CSNK2B | |
| SCHEMBL6185175 | 0.88 | PIK3CG (0.53) | PIK3CGDYRK1ACSNK2A2CLK1CSNK2B | |
| SCHEMBL6835909 | 0.85 | PIK3CG (0.53) | PIK3CGDYRK1ACSNK2A2CLK1CSNK2B | |
| SCHEMBL6835911 | 0.85 | PIK3CG (0.53) | PIK3CGDYRK1ACSNK2A2CLK1CSNK2B | |
| SCHEMBL6185079 | 0.83 | PIK3CG (0.51) | PIK3CGDYRK1ACSNK2A2CLK1CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1581529-A1 | BENZOXAZINES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3KS | WARNER-LAMBERT COMPANY (US) | 2005-10-05 | — | — | EP | claimed |
| US-20040138199-A1 | Benzoxazines and derivatives thereof as therapeutic agents | GOGLIOTTI ROCCO DEAN (US) | 2004-07-15 | — | — | US | claimed |
| WO-2004056820-A1 | BENZOXAZINES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3KS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | claimed |
| EP-1581529-A1 | BENZOXAZINES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3KS | WARNER-LAMBERT COMPANY (US) | 2005-10-05 | — | — | EP | disclosed |
| US-20040138199-A1 | Benzoxazines and derivatives thereof as therapeutic agents | GOGLIOTTI ROCCO DEAN (US) | 2004-07-15 | — | — | US | disclosed |
| WO-2004056820-A1 | BENZOXAZINES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3KS | WARNER-LAMBERT COMPANY LLC (US) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138199-A1 | Benzoxazines and derivatives thereof as therapeutic agents | XDH, TBXA2R, TBXAS1 | PIK3CG 4543/4885HSPD1 3188/4885HSPE1 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.